Pfizer wins right to challenge Prempro damages award; Asthma market flat until 2020 on Singulair rivals;

@FiercePharma: New issues at Ben Venue-J&J's CMO on Doxil-highlight pitfalls of contract manufacturing, WSJ reports. Piece | Follow @FiercePharma

> The Pennsylvania Supreme Court will review Pfizer's ($PFE) challenge to an $8.6 million punitive damages award in a Prempro case. News

> Takeda Pharmaceutical won European approval for its blood pressure drug Edarbi, saying that trials show its superiority to the highest doses of Daiichi Sankyo's Benicar and Novartis' Diovan. Item

> The asthma drug market will remain flat at around $14.4 billion through 2020, thanks in part to generic rivals for Merck's ($MRK) Singulair, Decision Resources concludes. Release

> Teva Pharmaceutical Industries ($TEVA) won an appeals court's backing for its Fentora patent, shutting out a Watson Pharmaceuticals ($WPI) copy until 2019. Story

> Watson Pharmaceuticals ($WPI) is plotting a 2012 launch for partner Antares Pharma's ($AIS) new treatment for overactive bladder, in a gel form. Article

> Amgen ($AMGN) will buy back about 83.3 million shares at $60 each, or 9.5% of its outstanding stock, as part of a $10 billion repurchase program. Report

> Women using antidepressants for premenstrual syndrome are more likely to get relief if they have multiple physical and psychological symptoms, rather than physical problems alone. More

> Depressive symptoms and impaired physical function tend to persist for long periods after an acute lung injury, a Johns Hopkins study found. Piece

Biotech News

@FierceBiotech: Alexza Pharma shares tank on FDA's safety concerns about Adasuve. Story | Follow @FierceBiotech

 @RyanMFierce: Some upbeat Ph2 data in breast cancer from Puma Biotech, which licensed the drug from Pfizer in October. Release  | Follow @RyanMFierce

@MaureenFierce: Reading: The loss of the middle (drugs and the people who find them). Story by @Dereklowe | Follow @MaureenFierce

 @MarkHFierce: But is the FDA bill an overall improvement? Curious what people think. | Follow @MarkHFierce

@FierceMedDev: Recently profiled them: Bluegrass Vascular starts 1st clinical study of the Surfacer inside-out access catheter system. Release | Follow @FierceMedDev

> Alexza Pharma shares tank on FDA's safety concerns about Adasuve. Item

> J&J locks in blood cancer compound in $975M pact. Story

And Finally... Men using three or more medications have higher rates of erectile dysfunction, according to a study. Report

Suggested Articles

A suspected cancer-causing impurity that has been found in some blood pressure medicines has now shown up in Zantac and some OTC antacids.

Roche is steamrolling with Ocrevus, and to maintain that lead, its touting long-term data that show the earlier it’s given, the better patients do.

New data shows a significant reduction in relapse rates in patients taking Novartis' repurposed cancer drug ofatumumab.